WO1999058137A1 - Preparation bio-pharmaceutique a base d'une culture vivante de bacillus et procede permettant de traiter des infections virales et bacteriennes ainsi qu'un etat de deficit immunitaire - Google Patents

Preparation bio-pharmaceutique a base d'une culture vivante de bacillus et procede permettant de traiter des infections virales et bacteriennes ainsi qu'un etat de deficit immunitaire Download PDF

Info

Publication number
WO1999058137A1
WO1999058137A1 PCT/RU1998/000208 RU9800208W WO9958137A1 WO 1999058137 A1 WO1999058137 A1 WO 1999058137A1 RU 9800208 W RU9800208 W RU 9800208W WO 9958137 A1 WO9958137 A1 WO 9958137A1
Authority
WO
WIPO (PCT)
Prior art keywords
immuno
well
bacterial infections
treating viral
bacillus
Prior art date
Application number
PCT/RU1998/000208
Other languages
English (en)
Russian (ru)
Inventor
Vitaly Georgievich Kostrovsky
Valery Ivanovich Sergienko
Alexandr Viktorovich Varand
Sergei Nikolaevich Gnedoi
Vyacheslav Vasilievich Pustovoi
Original Assignee
Vitaly Georgievich Kostrovsky
Valery Ivanovich Sergienko
Alexandr Viktorovich Varand
Sergei Nikolaevich Gnedoi
Pustovoi Vyacheslav Vasilievic
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vitaly Georgievich Kostrovsky, Valery Ivanovich Sergienko, Alexandr Viktorovich Varand, Sergei Nikolaevich Gnedoi, Pustovoi Vyacheslav Vasilievic filed Critical Vitaly Georgievich Kostrovsky
Priority to CA002288993A priority Critical patent/CA2288993A1/fr
Priority to AU88921/98A priority patent/AU8892198A/en
Priority to JP55155499A priority patent/JP2002521002A/ja
Publication of WO1999058137A1 publication Critical patent/WO1999058137A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/217—IFN-gamma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • C12N1/205—Bacterial isolates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
    • C12R2001/00—Microorganisms ; Processes using microorganisms
    • C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
    • C12R2001/07—Bacillus
    • C12R2001/10—Bacillus licheniformis

Definitions

  • the invention is subject to the field of medicine, and specifically to the creation of a drug having anti-bacterial and anti-inflammatory activity, as well as an immune system.
  • One of the products of this grouper is not devoid of a whole number of disadvantages: the result of their activity depends on the incidence of infection, the onset of the business, the individual is operating; injections of the body often cause harmful undesirable reactions (hypertension, headache and muscle pain, nausea, vomiting); in a number of cases, antibodies are used that neutralize the interior, which reduces the therapeutic effect and can prevent allergic reactions; is ⁇ lz ⁇ vanie ine ⁇ tsi ⁇ nny ⁇ ⁇ m s ⁇ yazhen ⁇ with ⁇ vyshennym ⁇ is ⁇ m ⁇ e ⁇ edachi vi ⁇ us ⁇ v ge ⁇ a ⁇ i ⁇ a and ⁇ ICH: ine ⁇ tsi ⁇ nnye ⁇ my in ⁇ e ⁇ e ⁇ n ⁇ v ⁇ n ⁇ si ⁇ eln ⁇ d ⁇ gi, ⁇ e ⁇ mu in ⁇ ealn ⁇ y ⁇ liniches ⁇ y ⁇ a ⁇ i ⁇ e e ⁇ i ⁇ e ⁇ a ⁇ a ⁇ y imeyu ⁇ ⁇ g ⁇
  • a whole number of drugs are registered and successfully used: baktisubtil (Ukraine), flinvin-BS (Yugoslavia), bi-sorbent (Ukraine). These drugs are used for the treatment of dyspepsia, diarrhea, enteritis, colitis, cystic erythematosus, diarrhea, dietsis, eczema, and allergic diseases. Eubotic therapy keeps the effectiveness of antibacterials and sulphonamides inactive.
  • the closest to the present invention is the product “Subalin”.
  • the product delivers free operation on the basic live culture of the Regular Strain ⁇ .
  • a well-known biological product operates on the basis of the biomass ⁇ . ⁇ Segment ⁇ in the amount of 1 * 10 9 ⁇ in 1 g of the preparation and is intended for use in the region.
  • P ⁇ s ⁇ avlennaya goal ⁇ eshae ⁇ sya ⁇ em, ch ⁇ in bi ⁇ e ⁇ a ⁇ a ⁇ e, s ⁇ de ⁇ zhaschem ⁇ e ⁇ mbinan ⁇ ny sh ⁇ amm ⁇ asShi ⁇ ⁇ i ⁇ I ⁇ , ⁇ dutsi ⁇ uyuschy al ⁇ a-2-in ⁇ e ⁇ e ⁇ n chel ⁇ ve ⁇ a, d ⁇ lni ⁇ eln ⁇ s ⁇ de ⁇ zhi ⁇ sya live ⁇ ul ⁇ u ⁇ a ⁇ asShi ⁇ ⁇ s ⁇ esh ⁇ ggsh ⁇ ⁇ i next s ⁇ n ⁇ shenii ⁇ m ⁇ nen ⁇ v:
  • ⁇ As a part of the file, components that are usually used to make the table, such as a glitch, may be used. acid, aluminum hydroxide, calcium and t. ⁇ . in general, in such cases, (for foreign use). ⁇ ga ⁇ vy and ire ⁇ . gels - for external use.
  • Bi ⁇ a ⁇ matsev ⁇ iches ⁇ y ⁇ e ⁇ a ⁇ a ⁇ on ⁇ sn ⁇ ve sele ⁇ tsi ⁇ nny ⁇ sh ⁇ amm ⁇ v ⁇ da ⁇ asShi ⁇ (in vege ⁇ a ⁇ ivn ⁇ y and s ⁇ v ⁇ y ⁇ me) was is ⁇ lz ⁇ van in ⁇ aches ⁇ ve vesches ⁇ va, ⁇ bladayuscheg ⁇ an ⁇ ivi ⁇ usn ⁇ y and an ⁇ iba ⁇ e ⁇ ialn ⁇ y a ⁇ ivn ⁇ s ⁇ yu in ⁇ a ⁇ iches ⁇ i ⁇ ⁇ liniches ⁇ i ⁇ usl ⁇ viya ⁇ , ⁇ e ⁇ a ⁇ a ⁇ ⁇ luchil usl ⁇ vn ⁇ e name "De ⁇ e ⁇ an ⁇ ».
  • the drug showed a high clinical efficacy in the treatment of various diseases of an infectious and non-communicable disease:
  • “DEPRECAN- ⁇ ” is an eubiotic treatment of a new drug based on the live culture of Vasco Shi ⁇ , which contains the alpha-2 gene of the human being.
  • the use of “Depecan- ⁇ ” means that dropping of bacteria into the intestine is possible, where there is a possibility of exchange and transfer of the equipment to them.
  • DEPRECAN-I can be successfully used in the treatment of infections caused by the viruses of EEGR ⁇ c ⁇ réelle ⁇ and ⁇ .
  • ⁇ ,
  • crizously a great encephalitis.
  • human viral symptoms simple viral infection, slow viral infection (including multiple sclerosis), segregation.
  • the used bacteria of the USA class are distinguished by their high resistance to gastrointestinal tracts and the possibility of settling. At the same time, inside the bacterium, they are multiplied in W for 2 days.
  • Depekan- ⁇ with success is used for the treatment of not only basic, but also secondary bacterial enteric infections.
  • Dermatocyanine is used for the treatment and treatment of dysbacteriosis, enteritis, enteritis, dysentery, digestive and allergic food. cholecystitis, blood-sickness, herpes, tick-borne encephalitis, acute tonsillitis, easy-to-treat diseases, severe infections, and also for allergies
  • the drug is prescribed in a dose of 1 tablet two or four times in a day, preferably not on an empty stomach, with an interval of 4-12 hours before recovery. ⁇
  • ⁇ For the purpose of more efficient settlement of the area of the city and the main area of food, it is advisable not to drink and to keep the food in good condition.
  • the drug is given 1-2 times a day in a 5-day period.
  • the drug does not recommend the simultaneous administration of antibiotics and sulphanilamides, which shorten the viability of 6
  • Depecan- ⁇ is a drug for the treatment of bacterial, viral infections and non-invasive immunodeficiencies.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Virology (AREA)
  • Biotechnology (AREA)
  • Communicable Diseases (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Cette invention se rapporte au domaine de la médecine et concerne essentiellement une préparation à base d'une culture vivante de Bacillus. Cette préparation contient, outre une matière de charge ordinaire, une souche recombinante de B. subtilis produisant l'alpha-2-interféron humain ainsi qu'une culture vivante de B. licheniformis, ceci dans des proportions prédéterminées. Cette préparation permet de traiter des infections virales telles que l'hépatite, l'herpès, l'encéphalite, etc., des infections bactériennes telles que l'entérite, la colite, la chlamydiose, la vaginite, etc., ainsi que des états de déficit immunitaire. Cette invention permet d'accroître le nombre des moyens qui permettent de lutter contre les infections bactériennes et virales ainsi que contre les états de déficit immunitaire sans avoir recours à des procédés invasifs.
PCT/RU1998/000208 1998-05-12 1998-07-06 Preparation bio-pharmaceutique a base d'une culture vivante de bacillus et procede permettant de traiter des infections virales et bacteriennes ainsi qu'un etat de deficit immunitaire WO1999058137A1 (fr)

Priority Applications (3)

Application Number Priority Date Filing Date Title
CA002288993A CA2288993A1 (fr) 1998-05-12 1998-07-06 Preparation bio-pharmaceutique a base d'une culture vivante de bacillus et procede permettant de traiter des infections virales et bacteriennes ainsi qu'un etat de deficit immunitaire
AU88921/98A AU8892198A (en) 1998-05-12 1998-07-06 Bio-pharmaceutical preparation containing a live culture of bacillus and method for treating viral and bacterial infections as well as immuno-deficiency conditions
JP55155499A JP2002521002A (ja) 1998-05-12 1998-07-06 枯草菌の培養生菌に基づく生物薬剤、並びに細菌感染、ウイルス感染及び免疫不全症状の治療方法

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
RU98108318 1998-05-12
RU98108318/14A RU2156134C2 (ru) 1998-05-12 1998-05-12 Биофармацевтический препарат на основе живой культуры bacillus и способ лечения заболевания инфекционной природы

Publications (1)

Publication Number Publication Date
WO1999058137A1 true WO1999058137A1 (fr) 1999-11-18

Family

ID=20205503

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/RU1998/000208 WO1999058137A1 (fr) 1998-05-12 1998-07-06 Preparation bio-pharmaceutique a base d'une culture vivante de bacillus et procede permettant de traiter des infections virales et bacteriennes ainsi qu'un etat de deficit immunitaire

Country Status (6)

Country Link
JP (1) JP2002521002A (fr)
CN (1) CN1259873A (fr)
AU (1) AU8892198A (fr)
CA (1) CA2288993A1 (fr)
RU (1) RU2156134C2 (fr)
WO (1) WO1999058137A1 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003099326A1 (fr) * 2002-05-29 2003-12-04 Bayer Healthcare Ag Nouvelles utilisations de preparations de parapoxvirus

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2532657A1 (fr) * 1982-09-08 1984-03-09 Eni Ente Naz Idrocarb Vecteurs plasmides s'exprimant en bacillus subtilis et procede pour leur preparation
SU1648975A1 (ru) * 1988-04-15 1991-05-15 Оренбургский Государственный Медицинский Институт Штамм бактерий BacILLUS SUвтILIS, используемый дл получени молочного продукта, предназначенного дл лечени диатеза, дисбактериоза и бактериальных инфекций
US5061495A (en) * 1988-03-07 1991-10-29 Agricultural Genetics Company Limited Antibiotic derived from b. subtilis
WO1994014473A1 (fr) * 1992-12-22 1994-07-07 The Wellcome Foundation Limited Association therapeutique contenant l'interferon
RU2084233C1 (ru) * 1994-07-15 1997-07-20 Научно-исследовательский институт сельского хозяйства Северо-Востока им.Н.В.Рудницкого Способ получения пробиотика для ветеринарии

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2532657A1 (fr) * 1982-09-08 1984-03-09 Eni Ente Naz Idrocarb Vecteurs plasmides s'exprimant en bacillus subtilis et procede pour leur preparation
US5061495A (en) * 1988-03-07 1991-10-29 Agricultural Genetics Company Limited Antibiotic derived from b. subtilis
SU1648975A1 (ru) * 1988-04-15 1991-05-15 Оренбургский Государственный Медицинский Институт Штамм бактерий BacILLUS SUвтILIS, используемый дл получени молочного продукта, предназначенного дл лечени диатеза, дисбактериоза и бактериальных инфекций
WO1994014473A1 (fr) * 1992-12-22 1994-07-07 The Wellcome Foundation Limited Association therapeutique contenant l'interferon
RU2084233C1 (ru) * 1994-07-15 1997-07-20 Научно-исследовательский институт сельского хозяйства Северо-Востока им.Н.В.Рудницкого Способ получения пробиотика для ветеринарии

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003099326A1 (fr) * 2002-05-29 2003-12-04 Bayer Healthcare Ag Nouvelles utilisations de preparations de parapoxvirus

Also Published As

Publication number Publication date
CN1259873A (zh) 2000-07-12
CA2288993A1 (fr) 1999-11-18
JP2002521002A (ja) 2002-07-09
AU8892198A (en) 1999-11-29
RU2156134C2 (ru) 2000-09-20

Similar Documents

Publication Publication Date Title
AU2010216926B2 (en) Immunopotentiating composition and process for producing same
US20040067223A1 (en) Probiotic compositions for the treatment of inflammatory bowel disease
US20060088514A1 (en) Formulation comprising a bacterial strain
Arsene et al. Short review on the potential alternatives to antibiotics in the era of antibiotic resistance
Takahashi et al. New horizon of mucosal immunity and vaccines
CN103565848A (zh) 凝结芽孢杆菌在制备预防和治疗幽门螺杆菌感染制剂中的应用
EP0804227B1 (fr) Utilisation de dimere de lysozyme pour traiter le cancer
CN103402531A (zh) 作为抗生素治疗的多价合成化合物
ES2074037T3 (es) Uso del dimero de lisozima para la fabricacion de un medicamento para modular los mecanismos de defensa naturales.
CN110124012B (zh) 一种颗粒溶素作为多粘菌素类抗生素增效剂的应用
WO1999058137A1 (fr) Preparation bio-pharmaceutique a base d'une culture vivante de bacillus et procede permettant de traiter des infections virales et bacteriennes ainsi qu'un etat de deficit immunitaire
RU2155052C1 (ru) Комплексный антипаразитарный препарат, не обладающий иммуносупрессией
RU2262350C2 (ru) Вакцина для иммунопрофилактики и иммунотерапии заболеваний человека и животных, вызванных патогенными и условно-патогенными грамотрицательными микроорганизмами кишечной группы и их экзотоксинами, и способ ее получения (варианты), иммуноглобулиновый препарат (варианты) и способ его получения, иммунобиологический препарат, поликомпонентная вакцина
US6806253B2 (en) Immunodulatory complex and use thereof in helicobacter diseases
O'mahony et al. Formulation comprising a bacterial strain
RU2614730C1 (ru) Антибактериальное средство и способ лечения кишечного иерсиниоза, или псевдотуберкулеза, или эшерихиоза
CN116732006B (zh) 副溶血弧菌噬菌体解聚酶及其应用
MXPA94002284A (es) Complejo inmunomodulador anti-sida.
RU2225214C2 (ru) СПОСОБ ПРОФИЛАКТИКИ И ЛЕЧЕНИЯ ИНФЕКЦИИ, ВЫЗЫВАЕМОЙ ЭНТЕРОПАТОГЕННЫМИ ШТАММАМИ Escherichia coli O157:H7
CN1203819A (zh) 肠出血性大肠杆菌感染的预防和治疗
Sigal Antibiotics for the treatment of rheumatologic syndromes
CN106474126B (zh) 抗癌小分子化合物索拉非尼在治疗肝包虫病中的应用
Wang et al. Recent Advances in Bacterial Biofilm Studies: Formation, Regulation, and Eradication in Human Infections
RU2134956C1 (ru) Способ выращивания телят
RU2164143C2 (ru) Способ лечения острых и хронических кишечных заболеваний, лекарственный препарат и его форма

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 98804473.0

Country of ref document: CN

ENP Entry into the national phase

Ref document number: 2288993

Country of ref document: CA

Ref document number: 2288993

Country of ref document: CA

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 1998940704

Country of ref document: EP

AK Designated states

Kind code of ref document: A1

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH GM GW HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
WWW Wipo information: withdrawn in national office

Ref document number: 1998940704

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: KR

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase